# Infectious Diseases Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN-TD
- Date: 1873-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Martin Beaumont, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Leticia Navarro, MD, Infectious Diseases
- Urgency: Urgent, within two weeks, on the same day as his two-week primary care visit

## Referral question

New cavitary, smear-positive pulmonary tuberculosis in a 21-year-old dentist who drinks heavily. Please confirm the regimen and doses, advise on liver monitoring given his alcohol use, and advise on isolation, return to dental work, and the length of treatment. **S**

## Questions for the consultant

1. Do you agree with the regimen and the weight-based doses?
2. How should his liver be monitored, given his drinking, and when should the drugs be stopped?
3. When can he leave home isolation and return to treating patients?
4. How long should treatment last, given the cavity, and is the four-month rifapentine and moxifloxacin regimen an option?
5. When can ethambutol be stopped?
6. Is any other testing or follow-up needed from infectious diseases?

## Pertinent history

Two months of cough, blood-streaked sputum, night sweats, and weight loss to 58.0 kg (BMI 18.3); temperature 37.8 °C, oxygen saturation 95 percent. Chest X-ray: right upper lobe consolidation with a 3 cm cavity. First sputum smear for acid-fast bacilli 2+ today; two early-morning samples to follow, and a nucleic acid amplification test, culture, and susceptibility testing ordered. HIV, hepatitis B, and hepatitis C tests sent. Baseline ALT 34, AST 38, bilirubin 0.6, GGT 78 (high), albumin 3.4 (low), hemoglobin 12.6 (low), platelets 412 (high), HbA1c 5.2, creatinine 0.86. Visual acuity 85 letters in each eye with normal color vision. Alcohol: AUDIT 15, whiskey four or more evenings a week, often six or more drinks, mostly at late-night card games; mild alcohol use disorder; brief intervention given; safety assessment with no current risk. No other medicines; no known allergies. Plan: isoniazid 300 mg, rifampin 600 mg, pyrazinamide 1500 mg, ethambutol 1200 mg, and pyridoxine 50 mg daily by video-observed therapy with the health department, starting as soon as the amplification test confirms tuberculosis. Reported to the health department today; isolating at home. **S**

- John Henry Holliday was born on August 14, 1851, in Griffin, Georgia. **D**
- In 1866 Holliday's mother died of tuberculosis. **D**
- He enrolled at the Pennsylvania College of Dental Surgery in 1870 and graduated in 1872, then practiced dentistry in Atlanta before opening his own practice in Griffin. **D**
- Shortly after beginning his career as a dentist in Atlanta he developed a bad cough; doctors diagnosed tuberculosis and advised a move to a more arid climate. He developed chronic pulmonary tuberculosis. **D**
- He was diagnosed with tuberculosis in 1873 and moved west for a healthier, drier climate, arriving in Dallas, Texas, in September 1873. **D**
- He made his living at the card tables, aggravating his tuberculosis with heavy drinking and late nights. **D**

1 later historical claim is omitted because it describes events after the index age. See the teaching note.

Baseline: Hemoglobin: 12.6 g/dL (low); White cell count: 9.4 10*3/uL; Platelets: 412 10*3/uL (high); ALT: 34 U/L; AST: 38 U/L; Total bilirubin: 0.6 mg/dL; Alkaline phosphatase: 92 U/L; GGT: 78 U/L (high); Albumin: 3.4 g/dL (low); Creatinine: 0.86 mg/dL; eGFR: 124 mL/min/1.73 m²; Glucose: 90 mg/dL; HbA1c: 5.2%; Visual acuity, right eye (ETDRS letters): 85; Visual acuity, left eye (ETDRS letters): 85; AUDIT: 15; AUDIT-C: 9; PHQ-9: 6. All results are synthetic.

BP 112/70 mmHg; pulse 104 bpm; respirations 20/min; temperature 37.8 °C; oxygen saturation 95% on room air; weight 58 kg; BMI 18.3 kg/m². All vital signs are synthetic.

## Current medications

- No current medications. **S**

## Plan so far

- Standard treatment: isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks, by video-observed therapy with the health department, with pyridoxine. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016) **S**
- Monitoring: monthly symptom and weight check, sputum smear and culture monthly until two consecutive cultures are negative, liver tests at two weeks and monthly because of alcohol, and vision checks while on ethambutol. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006) **S**
- Public health: same-day report to the local health department, home isolation until noninfectious, and a contact investigation of his household, coworkers, and patients led by the health department. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005) **S**
- Alcohol care: brief intervention at diagnosis, a goal of no alcohol during treatment, counseling with a substance-use counselor, medication offered, AUDIT-C at each visit, and a safety review with the 988 Suicide & Crisis Lifeline at every visit. Guideline: Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**
